To our knowledge, no prior studies have directly linked CIP2A with CD31; thus, our results are the first to suggest a role for CIP2A in promoting angiogenesis, offering novel insights into its contribution to lung cancer progression. Here, PECAM1 is linked to lung carcinoma.